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Background: Mesenchymal stromal cells (MSCs) are proven to have immunosuppressive functions via various
mechanisms. These mechanisms were demonstrated by administering bone marrow derived human MSCs (hMSCs)
to graft versus host disease (GVHD) murine models.
Methods: BALB/c host mice were irradiated prior to receiving C57BL/6 donor T cell depleted bone marrow
(TCDBM) cells (negative control) and donor CD4+ T lymphocyte with (treatment group) or without hMSCs (positive
control). The presence of hMSCs in target tissues and lymphoid organs was documented by using in vivo imaging and
measuring the expression of EphB2 and ephrin-B2 by RTqPCR. Survival rate and GVHD score were also monitored.
Tissue sections were obtained for histopathologic analysis. Flow cytometry was used to document donor T cell
alloreactivity and expression of CCR5, CXCR3 and CCR7. ELISA was utilized to determine levels of proinflammatory
cytokines, RANTES (CCL5) and phosphorylated STAT 5A/B. RTqPCR was performed to quantify expression of CCL3 and
CXCL9. Western blotting was performed to qualitatively measure iNOS expression.
Results: Survival rate and GVHD score improved with hMSC treatment. Pathologic changes of GVHD were abrogated.
Documentation of suppression of RANTES, CCL3, CXCL9, CCR5 and CXCR3 with simultaneous decrease of donor T cell
alloreactivity was demonstrated 6 days after transplantation, along with reduction of levels of inflammatory cytokines,
suppression of STAT 5A/B phosphorylation, increased expression of CCR7 and increased production of nitrous oxide by
hMSCs. Documentation of homing of hMSCs to lymphoid organs and target tissues was also performed.
Conclusions: These mechanisms contribute to the current understanding of MSC mechanisms of immunosuppression
and forms a comprehensive picture of how they exert immunosuppression in an in vivo model of immune dysregulation.
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Mesenchymal stromal cells (MSCs) were first identified
from the bone marrow and are described as self-
renewing cells capable of differentiating into cells of the
mesodermal (bone, fat, cartilage cells) lineage [1]. In
vitro, they are adherent to the surface of plastic plates* Correspondence: gcfchan@hkucc.hku.hk
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unless otherwise stated.and flasks. These cells do not express markers such as
CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA
class II [2]. Its characteristic multipotentiality makes it a
promising candidate as an important agent in the field of
cellular therapy. Studies that involve differentiation of
MSCs into cells of the endodermal and ectodermal lineage
are currently underway hence MSCs’ possible use in the
fields of cardiovascular medicine, endocrinology, gastro-
enterology, neurology, orthopedics, pulmonology, and
dermatology [3-9].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cells were reported to be able to suppress T cell prolifer-
ation leading to various studies that attempted to explain
the mechanisms of immunonodulation induced by
MSCs and also paving the way for its probable clinical
utility in graft versus host disease (GVHD) [10]. Most of
these mechanisms were explained either by obtaining
MSCs of murine sources and infusing them to mice with
the alloreactive reaction dependent on the mouse immune
system (i.e. non-humanized GVHD models) [11,12] or by
acquiring hMSCs then administering them to immunode-
ficient mice whose immune system is reconstituted with
human immune cells (i.e. humanized GVHD models)
[13-15]. There are a few reports that used hMSCs admin-
istered to non-humanized GVHD model mice [16,17]. In
this study we explained the immunosuppressive mecha-
nisms of MSCs using bone marrow derived hMSCs in-
fused to non-humanized GVHD mice.
Results
hMSCs migrate towards GVHD target organs
In order to identify the earliest time we would be able to
detect the presence of hMSCs in the GVHD target or-
gans and to answer whether hMSCs home to these or-
gans, hMSCs were stained with CM-Dil and injected
into host mice at the time of transplantation. Migration
patterns were observed towards the liver, colon, lungs
and spleen. 6 days after transplantation, hMSCs can be
localized in the liver, colon lung and spleen of GHVD
host mice (Figure 1A-B).
EphB2 and ephrin-B2 are reported to be expressed by
MSCs [18]. Measuring their mRNA levels in host spleen,
colon and lungs by RT-qPCR gave us a clue of possible
hMSC migration to these organs. 6 days after transplant-
ation, we noted increased levels of EphB2 and ephrin-B2
in host mice spleen, colon and lungs treated with
hMSCs (Figure 1C) (Additional file 1).
Treatment with hMSCs protects GVHD mice from
death, results to lower GVHD scores, decreases patho-
logic changes of GVHD in target organs and suppresses
early donor T cell alloreactivity.
Documentation of the host mice’s long term survival
and GVHD score after being given multiple doses of
hMSCs were performed (days 0, 3 and 6 after transplant-
ation). Multiple doses are given to overcome the transi-
ent nature of the immunosuppressive effects of hMSCs
and keep the mice alive for a longer period. All the nega-
tive control group host mice that received donor
TCDBM cells survived for 80 days. The survival of posi-
tive control group host mice given TCDBM and CD4+
was approximately 30%, 80 days after transplantation.
Maximal death rates were observed around days 7–14
after transplantation. The group of mice given hMSCs
survived better than the positive control, with around80% of mice still alive 80 days after transplantation. The
differences in survival between the 3 groups are signifi-
cant (p = 0.0035) by log-rank (Mantel-Cox Test) analysis
of survival (Figure 2A). The clinical score also shows the
effect hMSCs have in systemic symptoms of GVHD (p =
0.006) (Figure 2B). An important early indicator for
acute GVHD is donor T cell expansion in the host mice.
Treatment of mice with hMSCs caused a marked reduc-
tion in donor T cell alloreactivity in the target organs
and lymphoid tissues (Figure 2C). In line with these
findings, a significant decrease in levels of proinflamma-
tory cytokines in host tissue, notably TNF-α in the
spleen (p = 0.0391), and IFN-γ in the spleen and colon
was noted (p = 0.030) (Figure 3A-B). Lastly, host spleen,
liver, colon, and lungs were harvested 14 days after
transplantation and were noted to have less prominent
GVHD features with hMSC treatment (Figure 4).
hMSCs cause increased production of iNOS
An increase in the production of the immunosuppressive
soluble mediator, nitric oxide, catalyzed by inducible nitric
oxide synthase (iNOS), plays a role in the mechanism of
immunosupression caused by MSCs, such as suppressing
proteins regulating T cell cycle proliferation. A significant
increase in levels of iNOS was noted in the host colon
upon treatment with hMSCs (p = 0.0215) (Figure 5A).
hMSCs cause suppression of STAT 5A/B phosphorylation
Suppression of signal transducer and activator of tran-
scription 5A/B (STAT 5A/B) phosphorylation is a known
key factor in T cell proliferation and may be a possible
explanation for the reduction in the number of T cells in
the target tissues ultimately resulting to suppression of
graft versus host reaction (GVHR). This phenomenon
was most notably observed in the host splenocytes
where there is very high T cell activity (p = 0.0007) but
was not significant in the colon (p = 0.7216) (Figure 5B).
hMSCs suppress expression of chemokine receptors CCR5
and CXCR3 and cognate ligands RANTES, CCL3 and CXCL9
Chemokine receptors expressed by donor T cells and che-
mokine ligands expressed by GVHD target tissues play a
critical role in donor T cell alloreactivity in GVHD [19]. In
terms of the ligands, a significant decrease in expression
of RANTES (CCL5) in host splenocytes (p = 0.0356) but
not in the colon (p = 0.3214) was noted (Figure 6A). Ana-
lysis via RT-qPCR of chemokine ligands CCL3 and CXCL9
was also performed. Suppression of these ligands in the
host spleen, colon and lungs was noted with hMSC
treatment (Figure 6B). Moreover, the number of cells
expressing the corresponding receptors CCR5 (receptor
for CCL3 and RANTES) and CXCR3 (receptor for
CXCL9) are also significantly decreased in the spleen
with hMSC treatment (Figure 6C).
Figure 1 (See legend on next page.)
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Figure 1 Detection of hMSC homing capacity. (A-B) In vivo imaging of hMSCs in GVHD host tissues. (C) mRNA levels of EphB2 and ephrin-B2
in GVHD host tissues. Lethally irradiated BALB/c host mice were given intravenous injections of 2 × 10^6. TCDBM cells and 0.25 × 10^6 CD4+ T
cells from C57BL/6 donors with or without 1 × 10^6 hMSCs. hMSCs are stained with CM-Dil prior to injection to host mice. (A) Fluorescent signals
from host liver (a), colon (b), lung (c)and spleen (d) 6d after transplantation without (1,2) or with (3,4) cotransplantation of hMSCs. Color bar
represents signal intensity code. (B) Quantification of the signals in the liver, colon, lung and spleen. (C) Expression of EphB2 and ephrin-B2 6d
after transplantation in BALB/c host spleen, colon and lung was measured by real-time RT-qPCR. Data were combined from 2 independent
experiments with 2 mice in each experiment (n = 4 *p<0.05).
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chemokine receptor CCR7
CCR7 prolonged survival of GVHD mice via increasing
the trafficking of MSCs to lymphoid organs [20]. We
noted that 6 days after transplantation, the number of cells
expressing CD3+ CCR7+ cell population increased with
hMSC treatment in the spleen of host mice (p = 0.04)
(Figure 6D).
Discussion
In this model, administration of hMSCs to nonhuma-
nized GVHD mouse models was performed. Immuno-
suppression was noted despite the probable immune
reactivity of human cells to murine cells. The hMSCs
served as a niche for engraftment in hematopoietic stem
cell transplantation in the murine models regardless of
the MSC source. Demonstration of the presence of
hMSCs in the host tissues was done via in vivo imaging.
hMSCs were localized in the liver, colon, lung and spleen
6 days after transplantation. CM-Dil was used because it
is known not to fade or leak to other cells even after a
long period [21]. The measurement of gene expression
of EphB2 and ephrin-B2, done during the same period,
also enabled documentation of probable homing of
hMSCs to lymphoid organs and target tissues. These
members of the erythropoietin-producing hepatocellular
(Eph) receptors and ligands were reported to be
expressed by hMSCs and contribute to its immunosup-
pressive activities via downregulation of T-cell expres-
sion of soluble mediators such as IFN-γ, TNF-α, IL-2
and IL-17. Other members of this family are important
regulators of angiogenesis and induction of inducible ni-
tric oxide synthase (iNOS) expression, an important me-
diator of the immunosuppressive activity of MSCs.
Moreover, binding of these receptors and ligands to cog-
nate receptors and ligands in T lymphocytes was re-
ported to decrease T lymphocyte proliferation [22]. Mice
given hMSCs survived better as compared to positive
control mice. Mice treated with hMSCs also had less se-
vere symptoms of GVHD as evidenced by lower GVHD
scores. Further investigation was done on the various
mechanisms that may support this phenomenon. Patho-
logic evidence of resolution of GVHR in the spleen,
lung, liver and colon was noted 14 days after transplant-
ation. With active GVHR, the spleen usually manifestspathologically as prominent cellular infiltration in the
splenic white pulp. In the lungs, this reaction is observed
as inflammatory cells that can be localized at the region
surrounding the bronchioles. Lung GVHR also presents
as areas of congestion in the alveolar areas. These in-
flammatory cells of GVHR are seen surrounding the
portal vein in the liver. The prominent feature of GVHR
in the colon, apart from inflammatory cellular infiltra-
tion is colonic crypt drop outs [23-26]. With hMSC
treatment these changes were noticeably abated. Sup-
pression of expansion of donor cells in the spleen, lung
and colon was noted 6 days after transplantation. This
phenomenon most probably is not a result of T cell
apoptosis [27]. This results to subsequent dampening of
the Th1 response and the release of proinflammatory cy-
tokines IFN-γ and TNF-α in the tissues [16,17,22,28].
Previous studies however demonstrated that the im-
munosuppressive activities of MSCs are dependent on
IFN-γ [11,29,30]. This means that initially an environ-
ment with high levels of IFN-γ is necessary for hMSCs
to exert their immunosuppressive effects and upon onset
of activity of hMSCs in the lymphoid organs and target
tissues (i.e. 6 days after transplantation) the levels of pro-
inflammatory cytokines decrease. Chemokine ligands
and receptors play a major role in alloreactivity and
probably the immunomodulatory activities employed by
hMSCs. RANTES (CCL-5) is produced by various cell
types that are involved in the allogeneic response such as
macrophages, lymphocytes, dendritic cells and endothelial
cells and causes recruitment of other cells to migrate to
sites of inflammation such as activated T cells, monocytes,
macrophages, dendritic cells and neutrophils [31]. In
addition to RANTES, CCL3 and CXCL9 are chemokine li-
gands expressed by target tissues of GVHD and cause mi-
gration of mainly Th1 cell subset population to the said
tissues. These ligands bind to their cognate receptors
CCR5 for CCL3 and RANTES, and CXCR3 for CXCL9
[19]. These ligands and receptors are reported to be upreg-
ulated in lymphoid tissues concomitant with the increase
in levels of IFN-γ at around 3 days after transplantation
[12]. This increased chemokine receptor-ligand expression
are probably necessary for migration of MSCs to lymphoid
organs before they home to target tissues to exert their im-
munosuppressive actions. We suspect that chemokine ex-
pression is initially upregulated for migration of hMSCs to
Figure 2 Determination of hMSC effect in alloreactivity. (A)
Differences in survival, (B) GVHD clinical score, and (C) donor T cell
expansion in the 3 groups of mice. Lethally irradiated BALB/c host
mice were given intravenous injections of 2 × 10^6 TCDBM cells
from C57BL/6 donors with or without 0.25 × 10 ^6 CD4+ T cells
from donors and 1x 10 ^6 hMSCs. Multiple doses of hMSCs at the
day of transplantation then 3d and 6d after transplantation were
given for observation of survival and GVHD score. A single dose of
hMSCs was given at the day of transplantation for testing of donor
T cell expansion. (A) Survival of irradiated hosts given TCDBM cells alone
(n = 10) or with 0.25 × 10^6 CD4+ T cells (n = 20) or with 0.25 × 10^6
CD4+ T cells and 1 × 10^6 hMSCs (n = 12) (p = 0.0035). (B) GVHD score
of host mice and (C) relative and absolute numbers of donor CD3 T cells
in BALB/c host tissue 6d after transplantation with TCDBM alone or with
CD4+ T cells , or CD4+ T cells and hMSCs. (*p <0.05). Data were
combined from a single experiment with 8 mice per group for the
GVHD scoring and 4 mice per group in the experiment for
determination of donor T cell engraftment.
Figure 3 Measurement of levels of proinflammatory cytokines.
(A) TNF-α. (B) IFN-γ. Lethally irradiated BALB/c host mice were given
intravenous injections of 2 × 10^6 TCDBM cells from C57BL/6 donors
with or without 0.25 × 10 ^6 CD4+ T cells from donors and 1 × 10^6
hMSCs. Tissue cytokine levels [TNF-α(A), IFN- (B)] of BALB/c hosts 6d
after transplantation *p<0.05. Data were combined from 2 independent
experiments with 4 mice in each experiment.
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Figure 4 Comparison of histopathological changes in host tissues of the 3 groups. Lethally irradiated BALB/c host mice were given
intravenous injections of 2 × 10^6 TCDBM cells from C57BL/6 donors with or without 0.25 × 10 ^6 CD4+ T cells from donors and 1 × 10 ^6
hMSCs. Multiple doses of hMSCs were given at the day of transplantation then 3d and 6d after transplantation. Host spleen, liver, colon and lung
are harvested 14d after transplantation and hematoxylin and eosin sections were prepared for light microscopy. Diminished graft versus host
response was noted upon treatment with hMSCs namely substantial white pulp cellular infiltration in the spleen, periportal inflammation in the
liver, loss of crypts in the colon and peribronchial inflammation and alveolar congestion in the lungs. Each specimen is a representative of 3 mice
from each treatment group. Magnification × 100 for panels A and D; × 200 for panels B and C.
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suppressed by the time enough hMSCs are in the area to
exert immunosuppressive actions. This way the hMSCs are
already in the lymphoid organs and target tissues ready to
release soluble immunosuppressive mediators, at the same
time, the downregulation of chemokine receptors and li-
gands limits migration of inflammatory cells to these areas
all in all resulting to reduction of GVHR. With CCR7, theresponse may be somehow different. CCR7 is a G-protein
coupled receptor expressed on T cells. They function to
direct T-cells to the lymphoid organs [32]. In a recent
study, MSCs transfected with CCR7 prolonged survival of
GVHD mice via directing migration of these CCR7 trans-
fected MSCs to secondary lymphoid organs. This increased
migration of MSCs causes immunosppression of donor T
cells in the vicinity of the MSCs [20]. The observation of
Figure 5 Measurement of immunosuppressive mediators. (A)
iNOS production in host colon. (B) Phosphorylated STAT 5A/B levels
in the host spleen and colon. Lethally irradiated BALB/c host mice
were given intravenous injections of 2 × 10^6 TCDBM cells from
C57BL/6 donors with or without 0.25 ×10 ^6 CD4+ T cells from
donors and 1 × 10 ^6 hMSCs. (A) Host colon was harvested 6d after
transplantation and iNOS expression detected by western blotting
method. Each lane contains 50 ug of protein. B-actin served as loading
control. Intensity of bands is expressed in INT × 10^4/mm^2 units and
analyzed using The Discovery series Quantity 1D Analysis software,
Biorad Laboratories, Inc., USA. *p = 0.0215. Data were combined from 3
independent experiments with 2-3 mice in each experiment. (B) For
testing the levels of phosphorylated STAT 5A/B in the host spleen
and colon, tissues were harvested 6d after transplantation and
levels were determined by using ELISA. (***p = 0.0007). Data were
combined from 2 independent experiments with 3-4 mice in
each experiment.
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hMSC treatment in the spleen of host mice probably pro-
motes the migration of hMSCs to lymphoid organs and
target organs for more efficient immunosuppression.
Inducible nitric oxide synthase (iNOS) is an enzyme
that catalyzes the production of nitrous oxide which has
been reported to affect T cell receptor signaling, cyto-
kine receptor expression and production [12]. Produced
by MSCs, they are also reported to cause suppression of
STAT5 phosphorylation, causing probable inhibition of
T cell proliferation [33]. STAT 5 is part of the Jak/STAT
signaling pathway which is activated by tyrosine kinases.
Phosphorylation of this protein results to their migration
to the nucleus where they function as transcription fac-
tors regulating T cell proliferation [34]. An increase in
iNOS production by hMSCs, accompanied by a simul-
taneous suppression of STAT5A/B phosphorylation
thereby causing decreased T cell proliferation was noted.
These activities cumulatively results to immunosuppres-
sion and may explain the improvement of GVHD scores
and survival rates of hMSC treated host GVHD mice.
To date there are conflicting reports whether cell to
cell contact between MSCs and T cells or soluble factors
are the main mediators of T cell suppression [29,35].
The recent reports of interaction between members of
the ephrin family of receptors and ligands in both MSCs
and T cells and wide studies on soluble factors reported
to be secreted by MSCs, such as IDO, NO, PGE2 and
HLA-G5, most likely implies that the immunosuppres-
sive mechanism elicited by MSCs may be a combination
of the two [22,36]. GVL experiments were not per-
formed using this model. Previous reports demonstrated
that MSCs may not contribute to GVL but on the con-
trary may enhance tumor metastasis through secretion
of specific soluble factors [37]. Another study reported
that the immunosuppressive effect of MSCs favors
tumor growth in allogeneic animals [38].
Figure 6 Chemokine expression in host spleen and target
organs. (A) RANTES expression. (B) Expression of CCL3 and CXCL9.
(C-D) Expression of CCR5, CXCR3 and CCR7. Lethally irradiated BALB/
c host mice were given intravenous injections of 2 × 10^6 TCDBM
cells from C57BL/6 donors with or without 0.25 × 10 ^6 CD4+ T
cells from donors and 1 × 10 ^6 hMSCs. (A) Host spleen and colon
were harvested 6d after transplantation and RANTES expression
measured using ELISA (*p = 0.0356). Data were combined from 2
independent experiments with 3-4 mice in each experiment.
(B) Expression of CCL3 and CXCL9 6d after transplantation in
BALB/c host spleen, colon and lung were measured by RT-qPCR.
Data were combined from 2 independent experiments with 4-6 mice.
(C,D) Expression of CCR5, CXCR3 and CCR7 6d after transplantation in
BALB/c host spleen were measured by using trypan blue cell exclusion
assay and flow cytometry and expressed in absolute numbers of CD3+
CCR5+, CD3+ CXCR3+ (C) and CD3+ CCR7+ (D) splenocytes. Data
were combined from 2 independent experiments with 2-4 mice in
each experiment (*p<0.005).
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The mechanisms of immunosuppression brought about
by MSC treatment in GVHD remains elusive. hMSCs in-
fused to GVHD murine models increase the number of
cells expressing CCR7 contributing to homing of hMSCs
to lymphoid organs and then to target tissues of GVHD.
hMSCs release iNOS to suppress phosphorylation of
STAT 5A/B proteins and control T cell replication. The
chemokine ligands RANTES, CCL3 and CXCL9 are sup-
pressed along with their corresponding receptors CCR5
and CXCR3 resulting to diminished migration of allor-
eactive donor T cells to lymphoid organs and target tis-
sues and cytokine response. (Figure 7) Ultimately, these
mechanisms result to decreased GVHR which is reflect-
ive in the GVHD scores, histopathologic analysis of
GVHD target tissues and survival rates.
Methods
Animals
Wild-type C57BL/6 (H-2Kb) and BALB/c (H-2Kd) male
mice 6 to 8 weeks old were purchased from the breeding
facility of the Laboratory Animal Unit of the University of
Hong Kong. All mice were kept in a specific pathogen-free
facility. Animals were kept based on the guidelines set by
the Committee on the Use of Live Animals in Teaching
and Research (CULATR) of the University of Hong Kong
and the Department of Health Hong Kong.
hMSC culture and preparation of cell suspensions
hMSCs were obtained from bone marrow of three
healthy adult donors with the approval of the ethics
committee institutional review board of the Queen Mary
Hospital, The University of Hong Kong, cultured and
propagated using low glucose, L-glutamine supple-
mented Dulbecco’s Modified Eagle Medium, 100 U/mL
penicillin and 100 mg/mL streptomycin (Life Technolo-
gies, Carlsbad, CA). Prior to cell passaging every 3-4 days,
Figure 7 Immunosuppressive mechanisms of hMSCS in GVHD mouse models. (A) In the absence of hMSCs, upregulation of chemokine
receptors and ligands causes migration of donor T cells to the target tissues of GVHD causing increased T cell alloreactivity and Th1 response.
(B) With hMSC treatment, CCR7 increases migration of hMSCs to lymphoid organs and target tissues, then hMSCs produce soluble mediators
(iNOS) causing immunosuppression. These soluble mediators suppress ligands CCL3, RANTES and CXCL9 and corresponding receptors CCR5 and
CXCR3 with resultant decresased migration of donor T cells to the target tissues. This subsequently results to decreased TNF-α and IFN- γ. iNOS
also suppresses phosphorylation of STAT 5A/B proteins that regulates T cell proliferation. EphB2 and ephrin-B2 which are specifically found in
hMSCs also binds with T cells and suppress their proliferation.
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Fisher Scientific, Waltham, MA) with gentle scraping using
a 300 mm cell scraper (TPP, Trasadingen, Switzerland).
Cells were used at 5th-30th passage.
Single cell suspensions were prepared from donor
mice spleens, washed twice and filtered through a fine
metallic mesh. Mononuclear cells were isolated from the
solution using Lymphoprep Density Gradient Medium.
(Stemcell Technologies, Vancouver, BC). The isolate was
then enriched for CD4+ cells with anti-mouse CD4 mag-
netic microbeads using the MidiMACS system (Miltenyi
Biotech, Auburn, CA). The enriched cells were stained
with FITC anti-mouse CD4 (eBioscience, San Diego,
CA) and purity was ascertained at 95% per cent or more.TCDBM cells were prepared from donor mice femurs,
washed and filtered using a metallic mesh, stained with
anti-mouse CD90.2 (Thy1.2) Biotin (eBioscience, San
Diego, CA) and streptavidin microbeads (Miltenyi Biotec,
Auburn, CA) and passed over two consecutive MACS LS
separation columns. Adequacy of depletion was checked
by staining the eluate with APC/Cy7 anti-mouse CD3
(Biolegend, San Diego, CA) and ascertaining that the per-
centage of CD3+ cells is less than 5%.
Construction of GVHD model and clinical scoring
Induction of GVHD was done by lethal irradiation of
BALB/c host mice (800 cGy dose) using Gamma 3000
Elan as radiation source (Best Theatronics, Ottawa,
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cultured as mentioned above and injected via tail vein
within 24 hours. Host mice received either 2 × 10^6
TCDBM cells (negative control), 2 × 10 ^6 TCDBM cells
and 0.25 × 10^6 CD4+ spleen cells (positive control) or
2 × 10^6 TCDBM cells, 0.25 × 10^6 CD4+ spleen cells
and 1 × 10^6 hMSCs (treatment group). In all of the ex-
periments except for histopathologic analysis, analysis of
survival and GVHD score, 1 × 10^6 hMSCs are given at
the day of transplantation. For these three experiments,
1 × 10^6 hMSCs were given at the day of transplant-
ation, then at days 3 and 6 after transplantation. They
were given autoclaved water and feeds during the first
21 days after transplantation. The presence of GVHD
was assessed every day based on weight loss, posture, ac-
tivity, fur texture and skin integrity based on an estab-
lished criteria [39]. Survival and the presence of diarrhea
were also recorded every day. In compliance with the
university’s committee on the use of live animals in
teaching and research, mice were euthanized for weight
loss of >20% from its baseline weight.
Histopathologic analysis of GVHD
Histopathologic specimens from the host spleen, colon,
liver and lungs were harvested 14 days after transplant-
ation and fixed in 10% formaldehyde and embedded
into paraffin blocks. Sections of 4–5 um thickness were
obtained and stained with hematoxylin and eosin and
viewed under a light microscope for cellular and tissue
changes of acute GVHD (Carl Zeiss Axiovert 40 CFL,
Oberkochen, Germany). Images are captured using
Canon EOS 600D (Chichibu, STM, Japan) and are
exported as a series of .jpg files.
Detection of donor cell engraftment and chemokine
receptor expression
Single cell suspensions were prepared from host spleen,
lung, and colon by mechanical disruption and filtering
using a metallic mesh. Live cells were quantified by using
Trypan blue exclusion cell assay. The following fluorescent-
conjugated antibodies were used for flow cytometry: APC/
Cy7 anti-mouse CD3 (Biolegend, San Diego, CA), PE anti-
mouse H-2K^b, APC anti-mouse CXCR3, PE anti-mouse
CCR5, PE anti-mouse CCR7 (eBioscience, San Diego, CA).
Samples were run using a four fixed-aligned laser flow cyt-
ometer and data were analyzed using BD FACS Diva^TM
software (Becton Dickinson, Mountain View, CA) and
FlowJo software (TreeStar, Ashland, OR).
Detection of TNF-α, IFN-γ, RANTES, phosphorylated STAT
5A/B and inducible nitric oxide synthase
Specimens from host spleen, lung and colon were mech-
anically disrupted and homogenized using a handheld
homogenizer (Omni International, Kennesaw, GA).Supernatants were collected for ELISA of tumor necrosis
alpha (TNF-α), interferon gamma (IFN-γ), RANTES/
CCL-5 and phosphorylated STAT 5A/B (eBioscience,
San Diego, CA). Inducible nitric oxide synthase (iNOS)
levels were detected using polyclonal antibodies (Abcam,
Cambridge, UK) for western blotting. Total protein con-
centration in the supernantant was measured using
Bradford’s reagent. Supernatants were then subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE). Proteins were then transferred from
the gel to nitrocellulose membranes and ECL reagent
was used for visualization of the protein (GE Healthcare,
Buckinghamshire, UK).
Quantification of chemokine ligand and EphB2 and
ephrin-B2 expression by real time RT-qPCR
Frozen BALB/c host spleen, lung and colon tissues har-
vested 6 days after transplantation were mechanically
disrupted and homogenized as previously described and
total tissue RNA was isolated using a RNA extraction
kit. The isolated RNA is then subjected to reverse tran-
scription using oligo dT primer and PrimeScript reverse
transcript enzyme according to protocol provided by the
manufacturers. The synthesized cDNA was used for
quantification of mRNA by real-time quantitative PCR
by using SYBR premix Ex Taq II (Tli RNaseH Plus) and
7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA) (All kits and reagents from
Takara Bio Inc., Otsu-shi, Japan). The forward and re-
verse sequence for CCL3, CXCL9, EphB2, ephrin-B2
were obtained from previously published data [40,41].
Gene expression was calculated using the 2^-ΔCT
method relative to GADPH (glyceraldehyde 3-phosphate
dehydrogenase) CT values and were presented relative
to the expression of recipients given TCDBM only.
Localization of hMSCs in target tissues
hMSCs were stained with CM-Dil cell labeling solution for
20 minutes at 37°C and washed 3 times (Life Technologies,
Carlsbad, CA). 1 × 10^6 cells were given via tail vein to host
mice and at 6 days post transplantation, spleen, liver, lung
and colon were harvested and fluorescent signal intensity
of the stained cells in the tissues were measured at 550 nm
Abs spectrum using an in vivo imaging platform for small
animals. (CRi Maestro II, Cambridge Research & Instru-
mentation, Inc., Woburn, MA).
Statistical analysis
Analysis of mice survival was done by constructing
Kaplan-Meier survival curves using Prism Version 5.01
(GraphPad Software, San Diego, CA). Statistical differ-
ences in animal survival were analyzed by log-rank
(Mantel-Cox) test. Differences in fluorescence signals
using in vivo imaging were analyzed using Student t test
Robles et al. Experimental Hematology & Oncology  (2015) 4:13 Page 11 of 12to compare the group treated with hMSC with the group
not treated with hMSC. Differences in GVHD score, re-
covery of donor cells in host tissue, chemokine expres-
sion, EphB2 and ephrin-B2 expression, inflammatory
cytokine levels, inducible nitric oxide synthase produc-
tion, phosphorylated T-cell cycle regulatory protein
levels, were analyzed using Student t test to compare the
positive control and treatment groups. For all tests, a
p value of .05 or less was considered significant.
Additional file
Additional file 1: Table S1. Primer Sequences.
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